BioNTech | The conception of our mRNA platforms
WEBOur RiboMab (bispecific monoclonal antibody (mAb)-encoding mRNA) candidates represent the next generation of antibody-based cancer and infectious disease therapies overcoming current challenges of classic recombinant protein antibodies such as lengthy protein manufacturing processes.
BioNTech
WEBWe are developing a range of novel cell therapies in which the patient’s T cells are modified to target cancer-specific antigens. These include two platforms for the treatment of solid tumors: chimeric antigen receptor (CAR) T cell therapies and T …
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials
WEBAug 25, 2024 · BNT116 is specifically engineered to combat non-small cell lung cancer (NSCLC) and signifies a major progression in the field of personalized medicine. This cutting-edge vaccine employs messenger...
BioNTech treats first subject in Phase II cancer vaccine trial
WEBOct 20, 2023 · BioNTech has treated the first subject in a Phase II clinical trial of cancer vaccine candidate, autogene cevumeran (BNT122, RO7198457) to treat resected pancreatic ductal adenocarcinoma (PDAC), a type of solid tumour.
Three-year Phase 1 Follow-Up Data for mRNA-based ... - BioNTech
WEBApr 7, 2024 · By analyzing each patient’s tumor, BioNTech is able to identify the cancer mutations that may act as neoantigens. Each individual cancer vaccine encodes for neoantigen candidates with the highest likelihood of …
Clinical advances and ongoing trials of mRNA vaccines for cancer ...
WEBYears of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic.
BioNTech Expands Late-Stage Clinical Oncology Portfolio with …
WEBOct 19, 2023 · By analyzing each patient’s tumor, BioNTech is able to identify the cancer mutations that may act as neoantigens. Each individual cancer vaccine encodes for neoantigen candidates with the highest likelihood to …
BioNTech’s Founders on A.I. and the Future of Cancer Treatment
WEBDec 5, 2023 · The human papillomavirus vaccine provides powerful protection against the leading cause of cervical cancer and against a strong risk factor for anal cancer. Here’s what to know about the shot...
Platforms for Cell Therapy - BioNTech
WEBCell therapies are a new frontier in cancer medicines. Our diverse platforms cover a range of different approaches to enhance a T cell’s ability to recognize and destroy cancer cells.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
WEBMay 10, 2023 · A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell ...